Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 200
Filter
1.
Diabetologia ; 65(2): 301-314, 2022 02.
Article in English | MEDLINE | ID: mdl-34704121

ABSTRACT

AIMS/HYPOTHESIS: Energy-dense nutrition generally induces insulin resistance, but dietary composition may differently affect glucose metabolism. This study investigated initial effects of monounsaturated vs saturated lipid meals on basal and insulin-stimulated myocellular glucose metabolism and insulin signalling. METHODS: In a randomised crossover study, 16 lean metabolically healthy volunteers received single meals containing safflower oil (SAF), palm oil (PAL) or vehicle (VCL). Whole-body glucose metabolism was assessed from glucose disposal (Rd) before and during hyperinsulinaemic-euglycaemic clamps with D-[6,6-2H2]glucose. In serial skeletal muscle biopsies, subcellular lipid metabolites and insulin signalling were measured before and after meals. RESULTS: SAF and PAL raised plasma oleate, but only PAL significantly increased plasma palmitate concentrations. SAF and PAL increased myocellular diacylglycerol and activated protein kinase C (PKC) isoform θ (p < 0.05) but only PAL activated PKCɛ. Moreover, PAL led to increased myocellular ceramides along with stimulated PKCζ translocation (p < 0.05 vs SAF). During clamp, SAF and PAL both decreased insulin-stimulated Rd (p < 0.05 vs VCL), but non-oxidative glucose disposal was lower after PAL compared with SAF (p < 0.05). Muscle serine1101-phosphorylation of IRS-1 was increased upon SAF and PAL consumption (p < 0.05), whereas PAL decreased serine473-phosphorylation of Akt more than SAF (p < 0.05). CONCLUSIONS/INTERPRETATION: Lipid-induced myocellular insulin resistance is likely more pronounced with palmitate than with oleate and is associated with PKC isoforms activation and inhibitory insulin signalling. TRIAL REGISTRATION: ClinicalTrials.gov .NCT01736202. FUNDING: German Federal Ministry of Health, Ministry of Culture and Science of the State North Rhine-Westphalia, German Federal Ministry of Education and Research, European Regional Development Fund, German Research Foundation, German Center for Diabetes Research.


Subject(s)
Dietary Fats/administration & dosage , Insulin Resistance/physiology , Muscle, Skeletal/metabolism , Oleic Acid/administration & dosage , Palmitates/administration & dosage , Adult , Blood Glucose/metabolism , Calorimetry , Cross-Over Studies , Diglycerides/blood , Fatty Acids/blood , Female , Glucose Clamp Technique , Healthy Volunteers , Humans , Male , Palm Oil/administration & dosage , Protein Kinase C/blood , Safflower Oil/administration & dosage , Young Adult
2.
Protein Pept Lett ; 28(12): 1365-1371, 2021.
Article in English | MEDLINE | ID: mdl-34711151

ABSTRACT

Protein kinase C (PKC) is a family of protein kinase enzymes that can phosphorylate other proteins and influence their functions, such as signal transduction, cell survival, and death. Increased diacylglycerol (DAG) concentrations, which are typically observed raised in hyperglycemic situations such as diabetes mellitus, can also activate PKC enzymes (DM). On the other hand, PKC isomers have been shown to play an essential role in diabetes and many hyperglycemic complications, most importantly atherosclerosis and diabetic cardiomyopathy (DCM). As a result, blocking PKC activation via DAG can prevent hyperglycemia and related consequences, such as DCM. Wogonin is a herbal medicine which has anti-inflammatory properties, and investigations show that it scavenge oxidative radicals, attenuate nuclear factor-kappa B (NF-κB) activity, inhibit several essential cell cycle regulatory genes, block nitric oxide (NO) and suppress cyclooxygenase- 2 (COX-2). Furthermore, several investigations show that wogonin also attenuates diacylglycerol DAG levels in diabetic mice. Since the DAG-PKC pathway is linked with hyperglycemia and its complications, Wogonin-mediated DAG-PKC attenuation can help treat hyperglycemia and its complications.


Subject(s)
Atherosclerosis , Diabetic Cardiomyopathies , Diglycerides/blood , Flavanones/therapeutic use , Hyperglycemia , Protein Kinase C/metabolism , Animals , Atherosclerosis/drug therapy , Atherosclerosis/metabolism , Diabetic Cardiomyopathies/drug therapy , Diabetic Cardiomyopathies/metabolism , Humans , Hyperglycemia/drug therapy , Hyperglycemia/metabolism
3.
PLoS One ; 16(9): e0257856, 2021.
Article in English | MEDLINE | ID: mdl-34591942

ABSTRACT

Exocrine pancreatic insufficiency (EPI) causes chronic digestive dysfunction in cats, but its pathogenesis and pathophysiology are poorly understood. Untargeted metabolomics is a promising analytic methodology that can reveal novel metabolic features and biomarkers of clinical disease syndromes. The purpose of this preliminary study was to use untargeted analysis of the serum metabolome to discover novel aspects of the pathobiology of EPI in cats. Serum samples were collected from 5 cats with EPI and 8 healthy controls. The diagnosis of EPI was confirmed by measurement of subnormal serum feline trypsin-like immunoreactivity (fTLI). Untargeted quantification of serum metabolite utilized ultra-high-performance liquid chromatography-tandem mass spectroscopy. Cats with EPI had significantly increased serum quantities of long-chain fatty acids, polyunsaturated fatty acids, mevalonate pathway intermediates, and endocannabinoids compared with healthy controls. Diacylglycerols, phosphatidylethanolamines, amino acid derivatives, and microbial metabolites were significantly decreased in cats with EPI compared to healthy controls. Diacyclglycerols and amino acid metabolites were positively correlated, and sphingolipids and long-chain fatty acids were negatively correlated with serum fTLI, respectively. These results suggest that EPI in cats is associated with increased lipolysis of peripheral adipose stores, dysfunction of the mevalonate pathway, and altered amino acid metabolism. Differences in microbial metabolites indicate that feline EPI is also associated with enteric microbial dysbiosis. Targeted studies of the metabolome of cats with EPI are warranted to further elucidate the mechanisms of these metabolic derangements and their influence on the pathogenesis and pathophysiology of EPI in cats.


Subject(s)
Cat Diseases/diagnosis , Exocrine Pancreatic Insufficiency/veterinary , Metabolomics/methods , Amino Acids/blood , Animals , Blood Chemical Analysis , Case-Control Studies , Cat Diseases/blood , Cats , Chromatography, High Pressure Liquid , Diglycerides/blood , Exocrine Pancreatic Insufficiency/blood , Exocrine Pancreatic Insufficiency/diagnosis , Female , Male , Metabolome , Phosphatidylethanolamines/blood , Tandem Mass Spectrometry
4.
PLoS One ; 16(5): e0240764, 2021.
Article in English | MEDLINE | ID: mdl-34043632

ABSTRACT

Obesity is an epidemic internationally. While weight loss interventions are efficacious, they are compounded by heterogeneity with regards to clinically relevant metabolic responses. Thus, we sought to identify metabolic biomarkers that are associated with beneficial metabolic changes to weight loss and which distinguish individuals with obesity who would most benefit from a given type of intervention. Liquid chromatography mass spectrometry-based profiling was used to measure 765 metabolites in baseline plasma from three different weight loss studies: WLM (behavioral intervention, N = 443), STRRIDE-PD (exercise intervention, N = 163), and CBD (surgical cohort, N = 125). The primary outcome was percent change in insulin resistance (as measured by the Homeostatic Model Assessment of Insulin Resistance [%ΔHOMA-IR]) over the intervention. Overall, 92 individual metabolites were associated with %ΔHOMA-IR after adjustment for multiple comparisons. Concordantly, the most significant metabolites were triacylglycerols (TAGs; p = 2.3e-5) and diacylglycerols (DAGs; p = 1.6e-4), with higher baseline TAG and DAG levels associated with a greater improvement in insulin resistance with weight loss. In tests of heterogeneity, 50 metabolites changed differently between weight loss interventions; we found amino acids, peptides, and their analogues to be most significant (4.7e-3) in this category. Our results highlight novel metabolic pathways associated with heterogeneity in response to weight loss interventions, and related biomarkers which could be used in future studies of personalized approaches to weight loss interventions.


Subject(s)
Biomarkers/blood , Metabolomics , Obesity/blood , Weight Loss/physiology , Adult , Body Mass Index , Diglycerides/blood , Female , Humans , Insulin Resistance/physiology , Lipid Metabolism/physiology , Lipids/blood , Male , Mass Spectrometry , Middle Aged , Obesity/metabolism , Obesity/surgery , Obesity/therapy , Triglycerides/blood
5.
J Clin Endocrinol Metab ; 106(7): 2010-2020, 2021 06 16.
Article in English | MEDLINE | ID: mdl-33711157

ABSTRACT

CONTEXT: Few lipidomic studies have specifically investigated the association of circulating glycerolipids and type 2 diabetes (T2D) risk, especially among Asian populations. It remains unknown whether or to what degree fatty liver could explain the associations between glycerolipids and T2D. OBJECTIVE: We aimed to assess associations between plasma glycerolipids and incident T2D and to explore a potential role of liver fat accumulation in the associations. METHODS: This was a prospective cohort study with 6 years of follow-up. The study population included 1781 Chinese participants aged 50 to 70 years. The main outcome measure was incident T2D. RESULTS: At the 6-year resurvey, 463 participants had developed T2D. At the false discovery rate (FDR) of 5%, 43 of 104 glycerolipids were significantly associated with incident T2D risk after multivariate adjustment for conventional risk factors. After further controlling for glycated hemoglobin (HbA1c), 9 of the 43 glycerolipids remained significant, including 2 diacylglycerols (DAGs) (16:1/20:4, 18:2/20:5) and 7 triacylglycerols (TAGs) (46:1, 48:0, 48:1, 50:0, 50:1, 50:2, and 52:2), with relative risks (RRs) (95% CIs) ranging from 1.16 (1.05-1.27) to 1.23 (1.11-1.36) per SD increment of glycerolipids. However, additional adjustment for fatty liver index largely attenuated these findings (RR [95% CI] 0.88 [0.81 to 0.95] to 1.10 [1.01 to 1.21]). Mediation analyses suggested that the fatty liver index explained 12% to 28% of the glycerolipids-T2D associations (all P < 0.01). CONCLUSION: Higher plasma levels of DAGs and TAGs were associated with increased incident T2D risk in this Chinese population, which might be partially explained by liver fat accumulation.


Subject(s)
Diabetes Mellitus, Type 2/epidemiology , Fatty Liver/blood , Glycerides/blood , Severity of Illness Index , Aged , Asian People/statistics & numerical data , China/epidemiology , Diabetes Mellitus, Type 2/etiology , Diglycerides/blood , Fatty Liver/complications , Female , Glycated Hemoglobin/metabolism , Humans , Incidence , Lipidomics , Liver/metabolism , Male , Mediation Analysis , Middle Aged , Prospective Studies , Triglycerides/blood
6.
Cell Metab ; 32(2): 188-202.e5, 2020 08 04.
Article in English | MEDLINE | ID: mdl-32610096

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented threat to global public health. Herein, we utilized a combination of targeted and untargeted tandem mass spectrometry to analyze the plasma lipidome and metabolome in mild, moderate, and severe COVID-19 patients and healthy controls. A panel of 10 plasma metabolites effectively distinguished COVID-19 patients from healthy controls (AUC = 0.975). Plasma lipidome of COVID-19 resembled that of monosialodihexosyl ganglioside (GM3)-enriched exosomes, with enhanced levels of sphingomyelins (SMs) and GM3s, and reduced diacylglycerols (DAGs). Systems evaluation of metabolic dysregulation in COVID-19 was performed using multiscale embedded differential correlation network analyses. Using exosomes isolated from the same cohort, we demonstrated that exosomes of COVID-19 patients with elevating disease severity were increasingly enriched in GM3s. Our work suggests that GM3-enriched exosomes may partake in pathological processes related to COVID-19 pathogenesis and presents the largest repository on the plasma lipidome and metabolome distinct to COVID-19.


Subject(s)
Coronavirus Infections/blood , Coronavirus Infections/pathology , Exosomes/metabolism , G(M3) Ganglioside/blood , Gangliosides/blood , Pneumonia, Viral/blood , Pneumonia, Viral/pathology , Adult , Aged , Betacoronavirus , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , COVID-19 , Diglycerides/blood , Female , Humans , Male , Metabolome/physiology , Metabolomics/methods , Middle Aged , Pandemics , SARS-CoV-2 , Sphingomyelins/blood , Tandem Mass Spectrometry , Young Adult
7.
Drug Metab Dispos ; 48(10): 1092-1103, 2020 10.
Article in English | MEDLINE | ID: mdl-32719086

ABSTRACT

The action principles of traditional Chinese medicines (TCMs) feature multiactive components, multitarget sites, and weak combination with action targets. In the present study, we performed an integrated analysis of metabonomics, proteomics, and lipidomics to establish a scientific research system on the underlying mechanism of TCMs, and Schisandra lignan extract (SLE) was selected as a model TCM. In metabonomics, several metabolic pathways were found to mediate the liver injury induced by acetaminophen (APAP), and SLE could regulate the disorder of lipid metabolism. The proteomic study further proved that the hepatoprotective effect of SLE was closely related to the regulation of lipid metabolism. Indeed, the results of lipidomics demonstrated that SLE dosing has an obvious callback effect on APAP-induced lipidic profile shift. The contents of 25 diglycerides (DAGs) and 21 triglycerides (TAGs) were enhanced significantly by APAP-induced liver injury, which could further induce liver injury and inflammatory response by upregulating protein kinase C (PKCß, PKCγ, PKCδ, and PKCθ). The upregulated lipids and PKCs could be reversed to the normal level by SLE dosing. More importantly, phosphatidic acid phosphatase, fatty acid transport protein 5, and diacylglycerol acyltransferase 2 were proved to be positively associated with the regulation of DAGs and TAGs. SIGNIFICANCE STATEMENT: Integrated multiomics was first used to reveal the mechanism of APAP-induced acute liver failure (ALF) and the hepatoprotective role of SLE. The results showed that the ALF caused by APAP was closely related to lipid regulation and that SLE dosing could exert a hepatoprotective role by reducing intrahepatic diglyceride and triglyceride levels. Our research can not only promote the application of multicomponent technology in the study of the mechanism of traditional Chinese medicines but also provide an effective approach for the prevention and treatment of ALF.


Subject(s)
Acetaminophen/adverse effects , Chemical and Drug Induced Liver Injury/prevention & control , Drugs, Chinese Herbal/administration & dosage , Protective Agents/administration & dosage , Schisandra/chemistry , Administration, Oral , Animals , Cells, Cultured , Chemical and Drug Induced Liver Injury/blood , Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/pathology , Diglycerides/blood , Diglycerides/metabolism , Disease Models, Animal , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/isolation & purification , Hepatocytes , Humans , Lignans/administration & dosage , Lignans/isolation & purification , Lipid Metabolism/drug effects , Lipidomics , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mice , Primary Cell Culture , Protective Agents/chemistry , Protein Kinase C/metabolism , Proteomics , Triglycerides/blood , Triglycerides/metabolism
8.
Biomed Pharmacother ; 128: 110262, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32447214

ABSTRACT

Chemotherapy-induced intestinal mucositis (CIM) is a principal reason for reduced living quality of patients undergoing chemotherapy. Growing evidence showed gut microbiota played an important role in the development of intestinal mucositis. Dihydrotanshinone I (DHTS) is a liposoluble extract of Salvia miltiorrhiza Bunge with many bioactivities. Here we investigated the effect of DHTS on intestinal mucositis induced by 5-fluorouracil and irinotecan in mice. We detected the degree of intestinal mucosal damage and inflammatory response in CIM mice with or without DHTS administration. The body weight and disease activity index (DAI) of mice were monitored each day. H&E staining was used to evaluate pathological damage. The contents of interleukin 6 (IL-6), tumor necrosis factor (TNFα), diacylglycerol (DAO) and triglyceride (TG) in serum were determined by commercial kits. We also investigated the changes of fecal microbiota by 16S rRNA high-throughput sequencing. Spearman correlation analysis was used to evaluate the correlation between fecal microbiota and inflammatory factors. Tax4Funwas performed to infer the potential function of the microbial community. Results showed DHTS significantly reduced DAI, intestinal mucosal damage and inflammatory response in CIM mice by decreasing serum IL-6 and TNFα. In addition, there is an intense correlation between fecal microbiota and inflammatory factors. DHTS efficiently reversed disordered fecal microflora close to normal and increased the abundance of g__Akkermansia. DHTS also enriched bacterial species which promote butyric acid metabolism or negatively correlated with inflammatory factors. Besides, species enriched by DHTS in fecal microbiota were probably involved in glutamine production and ammonia oxidation. In conclusion, our study provides evidence that DHTS effectively attenuates CIM induced by 5-fluorouracil and irinotecan in mice. Regulation of the composition and function of fecal microbiota probably plays a critical role in the therapeutic effect of DHTS in CIM mice.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents , Bacteria/drug effects , Colon/drug effects , Furans/pharmacology , Gastrointestinal Microbiome/drug effects , Intestinal Mucosa/drug effects , Mucositis/prevention & control , Phenanthrenes/pharmacology , Animals , Bacteria/classification , Bacteria/metabolism , Colon/metabolism , Colon/microbiology , Colon/pathology , Diglycerides/blood , Disease Models, Animal , Feces/microbiology , Fluorouracil , Interleukin-6/blood , Intestinal Mucosa/metabolism , Intestinal Mucosa/microbiology , Intestinal Mucosa/pathology , Irinotecan , Male , Mice, Inbred C57BL , Mucositis/chemically induced , Mucositis/microbiology , Mucositis/pathology , Quinones , Triglycerides/blood , Tumor Necrosis Factor-alpha/blood
9.
Nutrients ; 12(2)2020 Feb 04.
Article in English | MEDLINE | ID: mdl-32033223

ABSTRACT

Conjugated linoleic acid (CLA) is a dietary supplement that has been shown to improve obesity. However, some authors have associated high doses of CLA supplementation with liver impairment and insulin resistance. The aim of this study was to assess whether the consumption of low doses of CLA maintained the beneficial effects on the main metabolic disturbances associated with metabolic syndrome (MetS) but prevented the occurrence of non-desirable outcomes associated with its consumption. Male Wistar rats, fed standard or cafeteria (CAF) diet for 12 weeks, were supplemented with three different low doses of CLA in the last three weeks. Both biochemical and H1 NMR-based metabolomics profiles were analysed in serum and liver. The consumption of 100 mg/kg CLA, but not doses of 200 and 300 mg/kg, ameliorated the increase in body weight gain as well as the serum concentrations of glucose, insulin, cholesterol, triglyceride, diglyceride, and total phospholipid induced by a CAF diet. In turn, CLA reverted the increase in lactate, alanine, and glucose concentrations in the liver of these animals, but enhanced hepatic cholesterol accumulation without any detrimental effect on liver function. In conclusion, a low dose of CLA corrected the adverse effects associated with MetS without compromising other metabolic parameters.


Subject(s)
Diet/methods , Dietary Supplements , Linoleic Acids, Conjugated/administration & dosage , Metabolic Syndrome/prevention & control , Weight Gain/drug effects , Animals , Blood Glucose/drug effects , Cholesterol/metabolism , Diet/adverse effects , Diglycerides/blood , Disease Models, Animal , Insulin/blood , Liver/metabolism , Male , Metabolic Syndrome/etiology , Phospholipids/blood , Rats , Rats, Wistar , Risk Factors , Triglycerides/blood
10.
Article in English | MEDLINE | ID: mdl-31978556

ABSTRACT

Ultrahigh-performance supercritical fluid chromatography - mass spectrometry (UHPSFC/MS), ultrahigh-performance liquid chromatography - mass spectrometry (UHPLC/MS), and matrix-assisted laser desorption/ionization (MALDI) - MS techniques were used for the lipidomic characterization of exosomes isolated from human plasma. The high-throughput methods UHPSFC/MS and UHPLC/MS using a silica-based column containing sub-2 µm particles enabled the lipid class separation and the quantitation based on exogenous class internal standards in <7 minute run time. MALDI provided the complementary information on anionic lipid classes, such as sulfatides. The nontargeted analysis of 12 healthy volunteers was performed, and absolute molar concentration of 244 lipids in exosomes and 191 lipids in plasma belonging to 10 lipid classes were quantified. The statistical evaluation of data included principal component analysis, orthogonal partial least square discriminant analysis, S-plots, p-values, T-values, fold changes, false discovery rate, box plots, and correlation plots, which resulted in the information on lipid changes in exosomes in comparison to plasma. The major changes were detected in the composition of triacylglycerols, diacylglycerols, phosphatidylcholines, and lysophosphatidylcholines, whereby sphingomyelins, phosphatidylinositols, and sulfatides showed rather similar profiles in both biological matrices.


Subject(s)
Exosomes/metabolism , Lipid Metabolism , Lipidomics/methods , Adult , Chromatography, High Pressure Liquid/methods , Chromatography, Supercritical Fluid/methods , Diglycerides/blood , Diglycerides/isolation & purification , Diglycerides/metabolism , Exosomes/chemistry , Healthy Volunteers , Humans , Lysophosphatidylcholines/blood , Lysophosphatidylcholines/isolation & purification , Lysophosphatidylcholines/metabolism , Male , Middle Aged , Phosphatidylcholines/blood , Phosphatidylcholines/isolation & purification , Phosphatidylcholines/metabolism , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Triglycerides/blood , Triglycerides/isolation & purification , Triglycerides/metabolism
11.
Diabetes Res Clin Pract ; 159: 107986, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31866525

ABSTRACT

AIMS: Hepatic insulin resistance, induced by fat, occurs before peripheral resistance and leads to prediabetes and diabetes. If insulin resistance is detected earlier, lifestyle changes could prevent or delay disease development. Therefore, we analysed lipids in the liver and serum of prediabetic and diabetic mice by MeV TOF-SIMS with a focus on diacylglycerols (DAGs) as the best predictor of (liver) resistance. METHODS: Glucose impairment was spontaneously developed or induced by HFD in NOD/LtJ mice, and prediabetic and diabetic mice were selected according to their glucose levels. MeV TOF-SIMS was applied to image the lipid distribution in the liver and to relatively quantify lipids related to insulin resistance in both the liver and serum. RESULTS: The same lipids were detected in the liver and serum but with different intensities between mice. The intensity of DAGs and fatty acids was higher in the diabetic than that in the prediabetic liver. Imaging of liver tissue showed a more compact density of prediabetic (non-fatty) than diabetic liver with DAG remodelling in diabetes. DAGs, which are greatly increased in diabetic serum, were successfully detected and quantified already in prediabetes. CONCLUSION: MeV TOF-SIMS applied to the serum presents an excellent tool for in vivo monitoring of disease development over time.


Subject(s)
Blood Chemical Analysis , Diabetes Mellitus, Experimental/metabolism , Diglycerides/analysis , Liver/chemistry , Prediabetic State/metabolism , Spectrometry, Mass, Secondary Ion/methods , Animals , Blood Chemical Analysis/methods , Diabetes Mellitus, Experimental/blood , Diglycerides/blood , Diglycerides/metabolism , Fatty Acids/analysis , Fatty Acids/blood , Fatty Acids/metabolism , Female , Insulin Resistance , Lipid Metabolism , Lipids/analysis , Lipids/blood , Liver/metabolism , Male , Mice , Mice, Inbred NOD , Prediabetic State/blood
12.
J Immunol Res ; 2019: 5836476, 2019.
Article in English | MEDLINE | ID: mdl-31355297

ABSTRACT

BACKGROUND: Mastocytosis is a condition characterized by the expansion and accumulation of mast cells (MCs) in various organs. The symptoms are related to the increased release of MC-derived mediators that exert local and distant effects. MCs are a source and target of phospholipase enzymes (PLs), which catalyze the cleavage of membrane phospholipids releasing lipid mediators (e.g., diacylglycerols (DAGs) and the endocannabinoid (EC) 2-arachidonoylglycerol (2-AG)). To date, there are no data on the role of these lipid mediators in mastocytosis. Here, we analyzed plasma levels of PLA2, PLC, DAG, ECs, and EC-related N-acylethanolamines in patients with mastocytosis. METHODS: In 23 patients with mastocytosis and 23 healthy individuals, we measured plasma PLA2 and PLC activities, DAG, 2-AG, anandamide (AEA), palmitoylethanolamide (PEA), and oleoylethanolamide (OEA). RESULTS: Plasma PLA2 and PLC activities were increased in mastocytosis patients compared to controls. Concentrations of DAG (18:1 20:4 and 18:0 20:4), two second messengers produced by PLC, were higher in mastocytosis compared to controls, whereas the concentrations of their metabolite, 2-AG, were not altered. AEA was decreased in mastocytosis patients compared to controls; by contrast, AEA congener, PEA, was increased. PLA2 and PLC activities were increased only in patients with mediator-related symptoms. Moreover, PLC activity was positively correlated with disease severity and tryptase concentrations. By contrast, AEA was negatively correlated with tryptase concentrations. CONCLUSIONS: PLs and some lipid mediators are altered in patients with mastocytosis. Our results may pave the way for investigating the functions of these mediators in the pathophysiology of mastocytosis and provide new potential biomarkers and therapeutic targets.


Subject(s)
Diglycerides/metabolism , Endocannabinoids/blood , Ethanolamines/blood , Mastocytosis/metabolism , Phospholipases A2/metabolism , Type C Phospholipases/metabolism , Adult , Aged , Arachidonic Acids/blood , Biomarkers/blood , Diglycerides/blood , Female , Humans , Male , Mastocytosis/blood , Mastocytosis/enzymology , Mastocytosis/pathology , Middle Aged , Phospholipases A2/blood , Polyunsaturated Alkamides/blood , Tryptases/blood , Type C Phospholipases/blood
13.
J Proteome Res ; 18(5): 2175-2184, 2019 05 03.
Article in English | MEDLINE | ID: mdl-30892048

ABSTRACT

The incidence of nonsmoking female patients with non-small cell lung cancer (NSCLC) has increased in recent decades; however, the pathogenesis of patients is unclear, and early diagnosis biomarkers are in urgent need. In this study, 136 nonsmoking female subjects (65 patients with NSCLC, 6 patients with benign lung tumors, and 65 healthy controls) were enrolled, and their metabolic profiling was investigated by using pseudotargeted gas chromatography-mass spectrometry. A total of 56 annotated metabolites were found and verified to be significantly different in nonsmoking females with NSCLC compared with the control. The metabolic profiling was featured by disturbed energy metabolism, amino acid metabolism, oxidative stress, lipid metabolism, and so on. Cysteine, serine, and 1-monooleoylglycerol were defined as the biomarker panel for the diagnosis of NSCLC patients. 98.5 and 91.4% of subjects were correctly distinguished in the discovery and validation sets, respectively. The biomarker panel was also useful for the diagnosis of in situ malignancy patients, with an accuracy of 97.7 and 97.8% in the discovery and validation sets, respectively. The study provides a biomarker panel for the auxiliary diagnosis of nonsmoking females with NSCLC.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/diagnosis , Cysteine/blood , Diglycerides/blood , Lung Neoplasms/diagnosis , Neoplasms/diagnosis , Serine/blood , Adult , Aged , Amino Acids/metabolism , Carcinoma, Non-Small-Cell Lung/blood , Case-Control Studies , Diagnosis, Differential , Early Detection of Cancer/methods , Energy Metabolism , Female , Gas Chromatography-Mass Spectrometry , Humans , Lipid Metabolism , Lung Neoplasms/blood , Metabolome , Middle Aged , Neoplasms/blood , Non-Smokers , Oxidative Stress , Sensitivity and Specificity
14.
Diabetes Metab ; 45(1): 39-46, 2019 01.
Article in English | MEDLINE | ID: mdl-29395809

ABSTRACT

AIM: The oral glucose tolerance test (OGTT), widely used as a gold standard for gestational diabetes mellitus (GDM) diagnosis, provides a broad view of glucose pathophysiology in response to a glucose challenge. We conducted the present study to evaluate metabolite changes before and after an oral glucose challenge in pregnancy; and to examine the extent to which metabolites may serve to predict GDM diagnosis in pregnant women. METHODS: Peruvian pregnant women (n=100) attending prenatal clinics (mean gestation 25 weeks) participated in the study with 23% of them having GDM diagnosis. Serum samples were collected immediately prior to and 2-hours after administration of a 75-g OGTT. Targeted metabolic profiling was performed using a LC-MS based metabolomics platform. Changes in metabolite levels were evaluated using paired Student's t-tests and the change patterns were examined at the level of pathways. Multivariate regression procedures were used to examine metabolite pairwise differences associated with subsequent GDM diagnosis. RESULTS: Of the 306 metabolites detected, the relative concentration of 127 metabolites were statistically significantly increased or decreased 2-hours after the oral glucose load (false discovery rate [FDR] corrected P-value<0.001). We identified relative decreases in metabolites in acylcarnitines, fatty acids, and diacylglycerols while relative increases were noted among bile acids. In addition, we found that C58:10 triacylglycerol (ß=-0.08, SE=0.04), C58:9 triacylglycerol (ß=-0.07, SE=0.03), adenosine (ß=0.70, SE=0.32), methionine sulfoxide (ß=0.36, SE=0.13) were significantly associated with GDM diagnosis even after adjusting for age and body mass index. CONCLUSIONS: We identified alterations in maternal serum metabolites, representing distinct cellular and metabolic pathways including fatty acid metabolism, in response to an oral glucose challenge. These findings offer novel perspectives on the pathophysiological mechanisms underlying GDM.


Subject(s)
Blood Glucose , Diabetes, Gestational/diagnosis , Metabolomics , Adolescent , Adult , Bile Acids and Salts/blood , Carnitine/analogs & derivatives , Carnitine/blood , Diabetes, Gestational/blood , Diglycerides/blood , Fatty Acids/blood , Female , Glucose/administration & dosage , Glucose Tolerance Test , Humans , Lipid Metabolism , Pregnancy , Young Adult
15.
J Am Heart Assoc ; 7(22): e010317, 2018 11 20.
Article in English | MEDLINE | ID: mdl-30571496

ABSTRACT

Background Venous thromboembolism ( VTE ) is a complex thrombotic disorder that constitutes a major source of mortality and morbidity. To improve understanding of the cause of VTE , we conducted a metabolomic analysis in a case-control study including 240 incident VTE cases and 6963 controls nested within 3 large prospective population-based cohorts, the Nurses' Health Study, the Nurses' Health Study II , and the Health Professionals Follow-Up Study. Methods and Results For each individual, we measured 211 metabolites and collected detailed information on lifestyle factors. We performed logistic regression and enrichment analysis to identify metabolites and biological categories associated with incident VTE risk, accounting for key confounders, such as age, sex, smoking, alcohol consumption, body mass index, and comorbid diseases (eg, cancers). We performed analyses of all VTEs and separate analyses of pulmonary embolism. Using the basic model controlling for age, sex, and primary disease, we identified 60 nominally significant VTE - or pulmonary embolism-associated metabolites ( P<0.05). These metabolites were enriched for diacylglycerols ( Ppermutation<0.05). However, after controlling for multiple testing, only 1 metabolite (C5 carnitine; odds ratio, 1.25; 95% confidence interval, 1.10-1.41; Pcorrected=0.03) remained significantly associated with VTE . After further adjustment for body mass index, no metabolites were significantly associated with disease after accounting for multiple testing, and no metabolite classes were enriched for nominally significant associations. Conclusions Although our findings suggest that circulating metabolites may influence the risk of incident VTE , the associations we observed were confounded by body mass index. Larger studies involving additional individuals and with broader metabolomics coverage are needed to confirm our findings.


Subject(s)
Venous Thromboembolism/etiology , Age Factors , Alcohol Drinking/adverse effects , Body Mass Index , Carnitine/biosynthesis , Case-Control Studies , Diglycerides/blood , Female , Humans , Logistic Models , Male , Metabolomics , Middle Aged , Risk Factors , Sex Factors , Smoking/adverse effects , Venous Thromboembolism/blood , Venous Thromboembolism/metabolism
16.
Nutrients ; 10(9)2018 Sep 17.
Article in English | MEDLINE | ID: mdl-30227635

ABSTRACT

Fatty liver is tightly associated with insulin resistance and the development of type 2 diabetes. I148M variant in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene is associated with high liver fat but normal insulin sensitivity. The underlying mechanism of the disassociation between high liver fat but normal insulin sensitivity remains obscure. We investigated the effect of I148M variant on hepatic lipidome of subjects with or without fatty liver, using the Lipidyzer method. Liver samples of four groups of subjects consisting of normal liver fat with wild-type PNPLA3 allele (group 1); normal liver fat with variant PNPLA3 allele (group 2); high liver fat with wild-type PNPLA3 allele (group 3); high liver fat with variant PNPLA3 allele (group 4); were analyzed. When high liver fat to normal liver fat groups were compared, wild-type carriers (group 3 vs. group 1) showed similar lipid changes compared to I148M PNPLA3 carriers (group 4 vs. group 2). On the other hand, in wild-type carriers, increased liver fat significantly elevated the proportion of specific DAGs (diacylglycerols), mostly DAG (FA18:1) which, however, remained unchanged in I148M PNPLA3 carriers. Since DAG (FA18:1) has been implicated in hepatic insulin resistance, the unaltered proportion of DAG (FA18:1) in I148M PNPLA3 carriers with fatty liver may explain the normal insulin sensitivity in these subjects.


Subject(s)
Diglycerides/blood , Fatty Liver/genetics , Insulin Resistance/genetics , Lipase/genetics , Liver/metabolism , Membrane Proteins/genetics , Polymorphism, Single Nucleotide , Adult , Aged , Biomarkers/blood , Blood Glucose/metabolism , Case-Control Studies , Fatty Liver/blood , Fatty Liver/diagnosis , Female , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Insulin/blood , Male , Middle Aged , Phenotype
17.
J Proteome Res ; 17(7): 2307-2317, 2018 07 06.
Article in English | MEDLINE | ID: mdl-29905079

ABSTRACT

This study explores the metabolic profiles of concordant/discordant phenotypes of high insulin resistance (IR) and obesity. Through untargeted metabolomics (LC-ESI-QTOF-MS), we analyzed the fasting serum of subjects with high IR and/or obesity ( n = 64). An partial least-squares discriminant analysis with orthogonal signal correction followed by univariate statistics and enrichment analysis allowed exploration of these metabolic profiles. A multivariate regression method (LASSO) was used for variable selection and a predictive biomarker model to identify subjects with high IR regardless of obesity was built. Adrenic acid and a dyglyceride (DG) were shared by high IR and obesity. Uric and margaric acids, 14 DGs, ketocholesterol, and hydroxycorticosterone were unique to high IR, while arachidonic, hydroxyeicosatetraenoic (HETE), palmitoleic, triHETE, and glycocholic acids, HETE lactone, leukotriene B4, and two glutamyl-peptides to obesity. DGs and adrenic acid differed in concordant/discordant phenotypes, thereby revealing protective mechanisms against high IR also in obesity. A biomarker model formed by DGs, uric and adrenic acids presented a high predictive power to identify subjects with high IR [AUC 80.1% (68.9-91.4)]. These findings could become relevant for diabetes risk detection and unveil new potential targets in therapeutic treatments of IR, diabetes, and obesity. An independent validated cohort is needed to confirm these results.


Subject(s)
Diabetes Mellitus, Type 2/etiology , Insulin Resistance , Metabolome , Obesity/metabolism , Biomarkers/blood , Diglycerides/blood , Fatty Acids, Unsaturated/blood , Humans , Predictive Value of Tests , Risk , Uric Acid/blood
18.
PLoS One ; 13(3): e0191815, 2018.
Article in English | MEDLINE | ID: mdl-29513680

ABSTRACT

BACKGROUND: Research from our laboratory, and that of other investigators, has demonstrated augmented levels of diacylglycerols (DAG) in the frontal cortex and plasma of subjects with Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). We have extended these observations to investigate the frontal cortex of subjects with Parkinson's disease (PD) and Lewy Body Disease (LBD), with and without coexisting pathologic features of AD. METHODS/PRINCIPAL FINDINGS: Utilizing a high-resolution mass spectrometry analytical platform, we clearly demonstrate that DAG levels are significantly increased in the frontal cortex of subjects with PD, LBD with intermediate neocortical AD neuropathology, and in LBD with established neocortical AD neuropathology. In the case of the PD cohort, increases in cortical DAG levels were detected in cases with no neocortical pathology but were greater in subjects with neocortical pathology. These data suggest that DAG changes occur early in the disease processes and are amplified as cortical dysfunction becomes more established. CONCLUSIONS: These findings suggest that altered DAG synthesis/metabolism is a common feature of neurodegenerative diseases, characterized by proteinopathy, that ultimately result in cognitive deficits. With regard to the mechanism responsible for these biochemical alterations, selective decrements in cortical levels of phosphatidylcholines in LBD and PD suggest that augmented degradation and/or decreased synthesis of these structural glycerophospholipids may contribute to increases in the pool size of free DAGs. The observed augmentation of DAG levels may be phospholipase-driven since neuroinflammation is a consistent feature of all disease cohorts. If this conclusion can be validated it would support utilizing DAG levels as a biomarker of the early disease process and the investigation of early intervention with anti-inflammatory agents.


Subject(s)
Diglycerides/metabolism , Frontal Lobe/metabolism , Lewy Body Disease/metabolism , Parkinson Disease/metabolism , Aged , Aged, 80 and over , Alzheimer Disease/blood , Alzheimer Disease/metabolism , Biomarkers/blood , Biomarkers/metabolism , Diglycerides/blood , Female , Frontal Lobe/pathology , Humans , Lewy Body Disease/blood , Male , Middle Aged , Neocortex/metabolism , Neocortex/pathology , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/metabolism , Parkinson Disease/blood
19.
Anal Chem ; 90(8): 5239-5246, 2018 04 17.
Article in English | MEDLINE | ID: mdl-29570972

ABSTRACT

Diacylglycerols (DAGs) are a subclass of neutral lipids actively involved in cell signaling and metabolism. Alteration in DAG metabolism has been associated with onset and progression of several human-related diseases. The structural diversity of DAGs and their low concentrations in biological samples call for the development of methods that are capable of sensitive identification and quantitation of each DAG species as well as rapid profiling when a biochemical pathway is perturbed. In this work, the thiol-ene click chemistry has been employed to introduce a charge-tag, namely, cysteamine (CA), at a carbon-carbon double bond (C═C) of unsaturated DAGs. This one-pot photochemical derivatization is fast (within 1 min), universal (monotagging) for DAGs varying in fatty acyl chain lengths and the number of C═Cs, and suitable for small sample volume (e.g., 1-50 µL plasma). Because of the presence of the amine group in CA, tagged DAGs showed at least 10 times increase in response to electrospray ionization as compared to conventional ammonium adduct formation. Low-energy collision-induced dissociation of CA tagged DAGs allowed confident assignment of fatty acyl composition. A neutral loss scan based on characteristic 95 Da loss (a combined loss of CA and H2O) of tagged DAGs has been established as a sensitive means for unsaturated DAG detection (limit of detection = 100 pM) and quantitation from mixtures. The analytical utility of CA tagging was demonstrated by shotgun analysis of unsaturated DAGs in human plasma, including samples from type 2 diabetes mellitus patients.


Subject(s)
Diglycerides/blood , Sulfhydryl Compounds/chemistry , Click Chemistry , Humans , Lipids/chemistry , Lipids/isolation & purification , Molecular Structure
20.
Clin Chim Acta ; 476: 107-110, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29146478

ABSTRACT

Cognitive decline is a devastating clinical condition, heavily correlated with age progression. In the cases of Alzheimer's disease, Parkinson's disease, and Lewy body disease, the common neuropathologies are proteinopathies and neuroinflammation. Herein, we review current lipidomics findings and conclude that brain and circulating diacylglycerols represent biomarkers of this ongoing sustained immune response, presumably involving microglia. We further hypothesize that a logical next step will be to evaluate biomarkers of immune activation in a cohort of patients with Mild Cognitive Impairment (MCI) and subsequently attempt to provide therapeutic intervention with anti-inflammatory therapy in MCI patients with immune activation. Although this is an urgent and theoretically safe therapeutic trial, it will likely necessitate government support.


Subject(s)
Dementia/immunology , Dementia/metabolism , Diglycerides/immunology , Proteins/metabolism , Anti-Inflammatory Agents/therapeutic use , Biomarkers/blood , Cognitive Dysfunction/blood , Cognitive Dysfunction/drug therapy , Cognitive Dysfunction/immunology , Cohort Studies , Dementia/blood , Dementia/pathology , Diglycerides/blood , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...